Drug Manufacturing Supply Chain

Drug Manufacturing Supply Chain

Eighty percent of the active and bulk chemical ingredients in U.S. drugs originate overseas,1  according to estimates by the Food and Drug Administration. The increasingly global and outsourced production of drugs creates vulnerabilities in the pharmaceutical supply system, which, without sufficient oversight by industry and regulators, can put patients’ lives at risk.

In early 2008, the U.S. Centers for Disease Control and Prevention identified a series of illnesses in dialysis patients, most of whom had received the blood thinner heparin.2 Investigations revealed that an adulterant with toxic effects had been introduced during heparin’s manufacture in China.3  Dozens of Americans were sickened, and some died.4  

Title VII of the FDA Safety and Innovation Act of 2012 establishes new safeguards for global drug production. The law directs FDA to prioritize inspections of the highest-risk manufacturing sites, overseas and domestic, and provides the agency with important new authority, such as the ability to block the importation of a drug or ingredient if the manufacturing plant has refused or delayed an FDA inspection.5

1 U.S. Government Accountability Office, Food and Drug Administration: Improvements Needed in the Foreign Drug Inspection Program (Publication No. GAO/HEHS-98-21, March 1998), http://www.gao.gov/assets/230/225564.pdf.

2 U.S. Centers for Disease Control and Prevention, “Acute Allergic-Type Reactions Among Patients Undergoing Hemodialysis: Multiple States, 2007–2008,” Morbidity and Mortality Weekly Report (Feb. 1, 2008),http://www.cdc.gov/mmwr/preview/mmwrhtml/mm57e201a1.htm.

3 Takashi Kei Kishimoto et al., “Contaminated Heparin Associated With Adverse Clinical Events and Activation of the Contact System,” New England Journal of Medicine (June 5, 2008) 358: 2457–67; and Steve Usdin, “The Heparin Story,” International Journal of Risk and Safety in Medicine (2009) 21: 99–103.

4 U.S. Government Accountability Office, Food and Drug Administration: Response to Heparin Contamination Helped Protect Public Health; Controls That Were Needed for Working With External Entities Were Recently Added (October 2010, Publication No. GAO-11-95) http://www.gao.gov/assets/320/311879.pdf.

5 U.S. Food and Drug Administration, “FDASIA Title VII Drug Supply Chain Provisions,” http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm365919.htm.

Additional Resources

The front facade of the Supreme Court of the United States in Washington, DC.

Agenda for America

A collection of resources to help federal, state, and local decision-makers set an achievable agenda for all Americans

Quick View

Data-driven policymaking is not just a tool for finding new solutions for emerging challenges, it makes government more effective and better able to serve the public interest. In the coming months, President Joe Biden and the 117th Congress will tackle a number of environmental, health, public safety, and fiscal and economic issues—nearly all of them complicated by the COVID-19 pandemic. To help solve specific, systemic problems in a nonpartisan fashion, Pew has compiled a series of briefings and recommendations based on our research, technical assistance, and advocacy work across America.


States of Innovation

Data-driven state policy innovations across America

Quick View

Data-driven policymaking is not just a tool for finding new solutions for difficult challenges. When states serve their traditional role as laboratories of innovation, they increase the American people’s confidence that the government they choose—no matter the size—can be effective, responsive, and in the public interest.